Clinical Guidelines for Drug-Related Peptic Ulcer, 2020 Revised Edition

키워드

참고문헌 (139)

1. 전형준, "Knee Pain and Its Severity in Elderly Koreans: Prevalence, Risk Factors and Impact on Quality of Life", Journal of Korean Medical Science, 28(12), pp.1807~1813 (2013), 대한의학회
2. Jung Hoon Lee, "Epidemiology of Heart Failure in Korea: Present and Future", Korean Circulation Journal, 46(5), pp.658~664 (2016), 대한심장학회
3. 심영광, "비스테로이드 항염제와 아스피린에 의한 소화성궤양", 대한소화기학회지, 67(6), pp.300~312 (2016), 대한소화기학회
4. Silverstein FE, "Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs : a randomized, double-blind, placebo-controlled trial", Ann Intern Med, 123, pp.241~249 (1995)
5. Silverstein FE, "Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis : the CLASS study : a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study", JAMA, 284, pp.1247~1255 (2000)
6. Bombardier C, "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group", N Engl J Med, 343, pp.1520~1528 (2000)
7. Schnitzer TJ, "Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial(TARGET), reduction in ulcer complications : randomised controlled trial", Lancet, 364, pp.665~674 (2004)
8. Bhatt DL, "Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events", N Engl J Med, 354, pp.1706~1717 (2006)
9. Moukarbel GV, "Gastrointestinal bleeding in high risk survivors of myocardial infarction : the VALIANT Trial", Eur Heart J, 30, pp.2226~2232 (2009)
10. Kim JI, "Changing prevalence of upper gastrointestinal disease in 28 893 Koreans from 1995 to 2005", Eur J Gastroenterol Hepatol, 21, pp.787~793 (2009)
11. Yang YJ, "Clinical characteristics of peptic ulcer perforation in Korea", World J Gastroenterol, 23, pp.2566~2574 (2017)
12. Lanza FL, "Guidelines for prevention of NSAID-related ulcer complications", Am J Gastroenterol, 104, pp.728~738 (2009)
13. Rostom A, "Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks", Aliment Pharmacol Ther, 29, pp.481~496 (2009)
14. Satoh K, "Evidence-based clinical practice guidelines for peptic ulcer disease 2015", J Gastroenterol, 51, pp.177~194 (2016)
15. 이준행, "비스테로이드소염제 관련 소화성궤양의 예방과 치료 가이드라인", 대한소화기학회지, 54(5), pp.309~317 (2009), 대한소화기학회
16. 김상균, "소화성궤양의 진단 가이드라인", 대한소화기학회지, 54(5), pp.279~284 (2009), 대한소화기학회
17. 정대영, "비출혈 소화성궤양 치료의 가이드라인", 대한소화기학회지, 54(5), pp.285~297 (2009), 대한소화기학회
18. 정일권, "출혈 소화성궤양 치료의 가이드라인", 대한소화기학회지, 54(5), pp.298~308 (2009), 대한소화기학회
19. 김지현, "특수한 질환에서 소화성궤양 치료의 가이드라인", 대한소화기학회지, 54(5), pp.318~327 (2009), 대한소화기학회
20. Higgins JPT, "Cochrane Handbook for Systematic Reviews of Interventions" (2017)
21. Kim SY, "Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity", J Clin Epidemiol, 66, pp.408~414 (2013)
22. Kim SY, "NECA’s Handbook for Clinical Practice Guideline Developer version 1.0", National Evidence-based Healthcare Collaborating Agency (NECA), ~ (2015)
23. Shorr RI, "Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease", Arch Intern Med, 153, pp.1665~1670 (1993)
24. García Rodríguez LA, "Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal antiinflammatory drugs", Lancet, 343, pp.769~772 (1994)
25. 이항락, "비스테로이드 항염제에 의한 위장관 손상의 위험인자 및 연령의 중요성", 대한소화기학회지, 44(5), pp.246~251 (2004), 대한소화기학회
26. Lanas A, "Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin nonsteroidal anti-inflammatory drugs, aspirin and combinations", Gut, 55, pp.1731~1738 (2006)
27. Kobata Y, "Risk factors for the development of gastric mucosal lesions in rheumatoid arthritis patients receiving long-term nonsteroidal anti-inflammatory drug therapy and the efficacy of famotidine obtained from the FORCE study", Mod Rheumatol, 19, pp.629~636 (2009)
28. Laine L, "Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients", Aliment Pharmacol Ther, 32, pp.1240~1248 (2010)
29. Milder TY, "“It looks after me”: how older patients make decisions about analgesics for osteoarthritis", Arthritis Care Res (Hoboken), 63, pp.1280~1286 (2011)
30. Chan FK, "Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers", Lancet, 350, pp.975~979 (1997)
31. Chan FK, "Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs : a randomised trial", Lancet, 359, pp.9~13 (2002)
32. Labenz J, "Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients : a randomised, double blind, placebo controlled, clinical trial", Gut, 51, pp.329~335 (2002)
33. Hawkey CJ, "Randomised controlled trial of Helicobacter pylori eradication in patients on nonsteroidal anti-inflammatory drugs : HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention", Lancet, 352, pp.1016~1021 (1998)
34. Lai KC, "Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs : a double-blind, placebo-controlled trial", Aliment Pharmacol Ther, 17, pp.799~805 (2003)
35. De Leest HT, "Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment : double-blind, randomized, placebo-controlled trial", Helicobacter, 12, pp.477~485 (2007)
36. Chan FK, "Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen", N Engl J Med, 344, pp.967~973 (2001)
37. Malfertheiner P, "Management of Helicobacter pylori infection-the Maastricht V", Florence Consensus Report, 2017, pp.66, 6~30
38. Lee JW, "Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012", Helicobacter, 18, pp.206~214 (2013)
39. Ekström P, "Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy : a Nordic multicentre study", Scand J Gastroenterol, 31, pp.753~758 (1996)
40. Bianchi Porro G, "Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment : a double blind placebo controlled study", Ital J Gastroenterol Hepatol, 30, pp.43~47 (1998)
41. Cullen D, "Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users", Aliment Pharmacol Ther, 12, pp.135~140 (1998)
42. Bianchi Porro G, "Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs : a prospective, placebo-controlled, double-blind, parallel-group study", Dig Liver Dis, 32, pp.201~208 (2000)
43. Lai KC, "Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal antiinflammatory drug users : a randomized trial", Aliment Pharmacol Ther, 18, pp.829~836 (2003)
44. Scheiman JM, "Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors", Am J Gastroenterol, 101, pp.701~710 (2006)
45. Desai JC, "Primary prevention of adverse gastroduodenal effects from short-term use of non-steroidal antiinflammatory drugs by omeprazole 20 mg in healthy subjects : a randomized, double-blind, placebo-controlled study", Dig Dis Sci, 53, pp.2059~2065 (2008)
46. Sugano K, "Randomised clinical trial:esomeprazole for the prevention of nonsteroidal anti-inflammatory drug-related peptic ulcers in Japanese patients", Aliment Pharmacol Ther, 36, pp.115~125 (2012)
47. Martin RM, "The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England : cohort studies", Br J Clin Pharmacol, 50, pp.366~372 (2000)
48. Gyawali CP, "Management of gastroesophageal reflux disease", Gastroenterology, 154, pp.302~318 (2018)
49. Gray SL, "Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women : results from the Women’s Health Initiative", Arch Intern Med, 170, pp.765~771 (2010)
50. Herzig SJ, "Acid-suppressive medication use and the risk for hospital-acquired pneumonia", JAMA, 301, pp.2120~2128 (2009)
51. Howell MD, "Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection", Arch Intern Med, 170, pp.784~790 (2010)
52. Park CH, "The association between the use of proton pump inhibitors and the risk of hypomagnesemia : a systematic review and meta-analysis", PLoS One, 9, pp.e112558~ (2014)
53. Sierra F, "Systematic review : proton pump inhibitor-associated acute interstitial nephritis", Aliment Pharmacol Ther, 26, pp.545~553 (2007)
54. Tai SY, "Risk of dementia from proton pump inhibitor use in Asian population : a nationwide cohort study in Taiwan", PLoS One, 12, pp.e0171006~ (2017)
55. Shah NH, "Proton pump inhibitor usage and the risk of myocardial infarction in the general population", PLoS One, 10, pp.e0124653~ (2015)
56. Lo WK, "Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth : a meta-analysis", Clin Gastroenterol Hepatol, 11, pp.483~490 (2013)
57. Freedberg DE, "The risks and benefits of longterm use of proton pump inhibitors : expert review and best practice advice from the American Gastroenterological Association", Gastroenterology, 152, pp.706~715 (2017)
58. Bolten W, "The gastroduodenal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis", Br J Rheumatol, 31, pp.753~758 (1992)
59. De Melo Gomes JA, "The safety of Arthrotec in patients with rheumatoid arthritis or osteoarthritis : an assessment of the upper gastrointestinal tract by endoscopy", Scand J Rheumatol Suppl, 96, pp.23~31 (1992)
60. Verdickt W, "A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis", Scand J Rheumatol, 21, pp.85~91 (1992)
61. Bardhan KD, "The prevention and healing of acute non-steroidal anti-inflammatory drug-associated gastroduodenal mucosal damage by misoprostol", Br J Rheumatol, 32, pp.990~995 (1993)
62. Graham DY, "Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group", Ann Intern Med, 119, pp.257~262 (1993)
63. Henriksson K, "Helicobacter pylori infection, ABO blood group, and effect of misoprostol on gastroduodenal mucosa in NSAID-treated patients with rheumatoid arthritis", Dig Dis Sci, 38, pp.1688~1696 (1993)
64. Melo Gomes JA, "Double-blind comparison of efficacy and gastroduodenal safety of diclofenac", misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis, 1993, pp.52, 881~885
65. Roth SH, "A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa", Arch Intern Med, 153, pp.2565~2571 (1993)
66. Agrawal NM, "Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers : a one-year study", Dig Dis Sci, 40, pp.1125~1131 (1995)
67. Piette F, "Efficacy of misoprostol in the prophylaxis of gastroduodenal lesions induced by short-term nonsteroidal antiinflammatory drug therapy in elderly patients : a multicenter double-blind, placebo-controlled trial", Rev Rhum Engl Ed, 64, pp.259~266 (1997)
68. Bocanegra TS, "Diclofenac", misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip : a randomized, placebo controlled trial. Arthrotec Osteoarthritis Study Group, 1998, pp.25, 1602~1611
69. Agrawal NM, "Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers", Clin Ther, 21, pp.659~674 (1999)
70. Rostom A, "Prevention of NSAIDinduced gastroduodenal ulcers", Cochrane Database Syst Rev, (4), pp.CD002296~ (2002)
71. Roth SH, "Cimetidine therapy in nonsteroidal anti-inflammatory drug gastropathy. Doubleblind long-term evaluation", Arch Intern Med, 147, pp.1798~1801 (1987)
72. Frank WO, "Reduction of indomethacin induced gastroduodenal mucosal injury and gastrointestinal symptoms with cimetidine in normal subjects", J Rheumatol, 16, pp.1249~1252 (1989)
73. Levine LR, "Nizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugs", Arch Intern Med, 153, pp.2449~2454 (1993)
74. Taha AS, "Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs", N Engl J Med, 334, pp.1435~1439 (1996)
75. Ten Wolde S, "High-dose ranitidine for the prevention of recurrent peptic ulcer disease in rheumatoid arthritis patients taking NSAIDs", Aliment Pharmacol Ther, 10, pp.347~351 (1996)
76. Hudson N, "Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration", Gastroenterology, 112, pp.1817~1822 (1997)
77. Laine L, "Double-blind randomized trials of single-tablet ibuprofen", highdose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers, 2012, pp.107, 379~386
78. Miner PB Jr, "Comparison of gastric pH with omeprazole magnesium 20. 6 mg(Prilosec OTC)o. m. famotidine 10 mg(Pepcid AC)b. d. and famotidine 20 mg b. d. over 14days of treatment", Aliment Pharmacol Ther, 25, pp.103~109 (2007)
79. McRorie JW, "Histamine2-receptor antagonists : rapid development of tachyphylaxis with repeat dosing", World J Gastrointest Pharmacol Ther, 5, pp.57~62 (2014)
80. Laine L, "A randomized doubleblind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production", Gastrointest Endosc, 42, pp.428~433 (1995)
81. Roth SH, "A longterm endoscopic evaluation of patients with arthritis treated with nabumetone vs naproxen", J Rheumatol, 21, pp.1118~1123 (1994)
82. Porto A, "Gastroduodenal tolerability of nimesulide and diclofenac in patients with osteoarthritis", Curr Ther Res, 59, pp.654~665 (1998)
83. Emery P, "Celecoxib versus diclofenac in long-term management of rheumatoid arthritis : randomised double-blind comparison", Lancet, 354, pp.2106~2111 (1999)
84. Laine L, "A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group", Gastroenterology, 117, pp.776~783 (1999)
85. Simon LS, "Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis : a randomized controlled trial", JAMA, 282, pp.1921~1928 (1999)
86. Hawkey C, "Comparison of the effect of rofecoxib(a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis : a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group", Arthritis Rheum, 43, pp.370~377 (2000)
87. Hawkey CJ, "Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials", Aliment Pharmacol Ther, 15, pp.1593~1601 (2001)
88. Kivitz A, "Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis", J Fam Pract, 51, pp.530~537 (2002)
89. Sikes DH, "Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis", Eur J Gastroenterol Hepatol, 14, pp.1101~1111 (2002)
90. Goldstein JL, "A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects", Aliment Pharmacol Ther, 18, pp.125~132 (2003)
91. Hawkey CJ, "Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo : a multicentre, randomised, double blind study", Gut, 52, pp.820~826 (2003)
92. Hunt RH, "The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events", Am J Gastroenterol, 98, pp.1725~1733 (2003)
93. Hunt RH, "Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib", Aliment Pharmacol Ther, 17, pp.201~210 (2003)
94. Rordorf C, "Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen : a pilot endoscopic study in healthy male subjects", Aliment Pharmacol Ther, 18, pp.533~541 (2003)
95. Girawan D, "Comparison of endoscopic gastric mucosa features after administration of piroxicam to meloxicam and their correlation with dyspepsia symptoms in elderly patient with knee osteoarthritis", Acta Med Indones, 36, pp.202~206 (2004)
96. Hawkey CC, "Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis", J Rheumatol, 31, pp.1804~1810 (2004)
97. Kivitz AJ, "Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis", Aliment Pharmacol Ther, 19, pp.1189~1198 (2004)
98. Scheiman JM, "A randomized, controlled comparison of ibuprofen at the maximal over-the-counter dose compared with prescription-dose celecoxib on upper gastrointestinal mucosal injury", Clin Gastroenterol Hepatol, 2, pp.290~295 (2004)
99. Goldstein JL, "A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years", Clin Ther, 28, pp.340~351 (2006)
100. Moberly JB, "A randomized, double-blind, one-week study comparing effects of a novel COX-2 inhibitor and naproxen on the gastric mucosa", Dig Dis Sci, 52, pp.442~450 (2007)
101. Sakamoto C, "Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy : a placebo-controlled, double-blind 2-week study", Aliment Pharmacol Ther, 37, pp.346~354 (2013)
102. Chan FK, "Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients : results of a randomized double-blind trial", Gastroenterology, 127, pp.1038~1043 (2004)
103. Farkouh ME, "An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs", Am J Cardiol, 103, pp.1227~1237 (2009)
104. Chan FK, "Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users", Gastroenterology, 144, pp.528~535 (2013)
105. Lai KC, "Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use", N Engl J Med, 346, pp.2033~2038 (2002)
106. Sugano K, "Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy : results of a prospective, multicenter, double-blind, randomized, double-dummy, activecontrolled trial", J Gastroenterol, 46, pp.724~735 (2011)
107. Scheiman JM, "Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid : a randomised, controlled trial(OBERON)", Heart, 97, pp.797~802 (2011)
108. Sanuki T, "Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease : a prospective randomized active-controlled trial", J Gastroenterol, 47, pp.1186~1197 (2012)
109. Sugano K, "Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users : the LAVENDER study", Gut, 63, pp.1061~1068 (2014)
110. Whellan DJ, "PA32540(a coordinated-delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg)versus enteric-coated aspirin 325 mg alone in subjects at risk for aspirin-associated gastric ulcers : results of two 6-month, phase 3 studies", Am Heart J, 168, pp.495~502 (2014)
111. Iwakiri R, "Randomised clinical trial : prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin", Aliment Pharmacol Ther, 40, pp.780~795 (2014)
112. Sung JJ, "Continuation of low-dose aspirin therapy in peptic ulcer bleeding : a randomized trial", Ann Intern Med, 152, pp.1~9 (2010)
113. ASGE Standards of Practice Committee, "The management of antithrombotic agents for patients undergoing GI endoscopy", Gastrointest Endosc, 83, pp.3~16 (2016)
114. Gralnek IM, "Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage : European Society of Gastrointestinal Endoscopy(ESGE)Guideline", Endoscopy, 47, pp.a1~a46 (2015)
115. Chan FK, "Management of patients on antithrombotic agents undergoing emergency and elective endoscopy : joint Asian Pacific Association of Gastroenterology(APAGE)and Asian Pacific Society for Digestive Endoscopy(APSDE)practice guidelines", Gut, 67, pp.405~417 (2018)
116. Witt DM, "Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding", Arch Intern Med, 172, pp.1484~1491 (2012)
117. Lee JK, "Risks related with withholding and resuming anticoagulation in patients with nonvariceal upper gastrointestinal bleeding while on warfarin therapy", Int J Clin Pract, 66, pp.64~68 (2012)
118. Qureshi W, "Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation", Am J Cardiol, 113, pp.662~668 (2014)
119. Antithrombotic Trialists’(ATT)Collaboration, "Aspirin in the primary and secondary prevention of vascular disease : collaborative meta-analysis of individual participant data from randomised trials", Lancet, 373, pp.1849~1860 (2009)
120. Pearce LA, "Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation", Am J Med, 109, pp.45~51 (2000)
121. Veitch AM, "Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants : British Society of Gastroenterology(BSG)and European Society of Gastrointestinal Endoscopy(ESGE)guidelines", Endoscopy, 48, pp.c1~ (2016)
122. Douketis JD, "Perioperative management of antithrombotic therapy : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines", Chest, 141(2 Suppl), pp.e326~e350S (2012)
123. Hawn MT, "Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents", JAMA, 310, pp.1462~1472 (2013)
124. Lanas A, "Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants", Am J Gastroenterol, 102, pp.507~515 (2007)
125. Massó González EL, "Proton pump inhibitors reduce the long-term risk of recurrent upper gastrointestinal bleeding : an observational study", Aliment Pharmacol Ther, 28, pp.629~637 (2008)
126. Lin KJ, "Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy", Gastroenterology, 141, pp.71~79 (2011)
127. Lauffenburger JC, "Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy", Pharmacotherapy, 35, pp.560~568 (2015)
128. Chan EW, "Prevention of dabigatranrelated gastrointestinal bleeding with gastroprotective agents : a population-based study", Gastroenterology, 149, pp.586~595 (2015)
129. Ray WA, "Association of proton pump inhibitors with reduced risk of warfarin-related serious upper gastrointestinal bleeding", Gastroenterology, 151, pp.1105~1112 (2016)
130. Sugano K, "How do we manage serious gastrointestinal adverse events associated with anti-thrombotic therapy", Expert Rev Gastroenterol Hepatol, 9, pp.5~8 (2015)
131. Agewall S, "Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy", Eur Heart J, 34, pp.1708~1713 (2013)
132. Teichert M, "Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment", Br J Haematol, 153, pp.379~385 (2011)
133. Hata M, "Incidence of drug interaction when using proton pump inhibitor and warfarin according to cytochrome P450 2C19(CYP2C19)genotype in Japanese", Thorac Cardiovasc Surg, 63, pp.45~50 (2015)
134. EINSTEIN Investigators, "Oral rivaroxaban for symptomatic venous thromboembolism", N Engl J Med, 363, pp.2499~2510 (2010)
135. Granger CB, "Apixaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 365, pp.981~992 (2011)
136. Kuwayama T, "Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation", J Arrhythm, 33, pp.619~623 (2017)
137. Bolek T, "The impact of proton pump inhibition on dabigatran levels in patients with atrial fibrillation", Am J Ther, 26, pp.e308~e313 (2019)
138. Bolek T, "Proton pump inhibition in patients treated with novel antithrombotic drugs: should we worry about thrombosis?", J Cardiovasc Pharmacol, 72, pp.71~76 (2018)
139. Hyun KR, "Population aging and healthcare expenditure in Korea", Health Econ, 25, pp.1239~1251 (2016)

관련 논문AI추천